Colorectal cancer remains a leading cause of oncologic mortality globally, requiring robust molecular biomarkers to guide personalized therapy. Recent investigations highlight the multifaceted role of FGA in colorectal cancer progression and invasion. Although clinicians traditionally viewed fibrinogen strictly as a coagulation factor, modern translational research proves its active role in tumor plasticity. Furthermore, aberrant synthesis of fibrinogen alpha chain within malignant colonic epithelium correlates with aggressive disease phenotypes and adverse patient outcomes. Understanding these intricate interactions provides clinicians with crucial insights into therapeutic resistance and disease monitoring.

Mechanistic Significance of FGA in Colorectal Cancer Pathogenesis

Comprehensive analysis of The Cancer Genome Atlas data reveals substantial upregulation of fibrinogen alpha chain transcript and protein levels in colorectal malignant tissues compared to adjacent normal mucosa. Similarly, independent clinical tissue cohorts confirm this distinct pattern of overexpression using immunohistochemical staining techniques. High cellular levels of the protein consistently align with adverse clinicopathological parameters, including aggressive histological subtype and extensive lymphatic vessel permeation. Consequently, patients exhibiting high tumor expression demonstrate significantly reduced overall survival and accelerated recurrence rates. Beyond its intracellular presence, preliminary clinical investigations also detect elevated concentrations of circulating protein in the serum of affected patients. Therefore, researchers hypothesize that this factor operates simultaneously as an autocrine tumor driver and a systemic indicator of aggressive malignancy. Pathologists frequently observe intense staining at the invasive tumor front, where neoplastic cells actively remodel the extracellular matrix. Moreover, this localized enrichment suggests a direct functional involvement in detaching cohesive epithelial sheets during early invasion. By characterizing these tissue expressions, clinicians can identify high-risk individuals who may benefit from closer postoperative follow-up and tailored adjuvant regimens.

Driving Epithelial-Mesenchymal Transition and Metastatic Potential

Metastatic dissemination represents the primary cause of colorectal cancer treatment failure, and cellular reprogramming serves as its fundamental biological engine. In vitro functional assays utilizing HCT116 colon cancer cell lines demonstrate that cellular overexpression directly triggers the epithelial-mesenchymal transition cascade. Specifically, elevated protein levels induce a marked downregulation of the pivotal cell adhesion protein E-cadherin. Concurrently, cells upregulate key mesenchymal markers, including Vimentin, Snail, and ZEB1. As a result, malignant cells shed their rigid epithelial polarity and acquire an elongated, migratory morphology. Transwell migration experiments confirm that this phenotypic conversion substantially enhances directional cellular motility and basement membrane invasion. In contrast, depleting the protein reverses these migratory advantages and restores epithelial characteristics. Furthermore, the loss of intercellular adhesion enables individual carcinoma cells to penetrate lymphatic channels and enter the mesenteric circulation. Thus, this regulatory cascade serves as a vital bridge linking extracellular matrix changes to intracellular transcriptional reprogramming. Understanding this invasive transition provides valuable opportunities to design targeted interventions that inhibit metastatic seeding before secondary organ colonization occurs.

Uncovering the USP-Catenin Complex and Stemness Signatures

Cancer stem cells sustain tumor initiation, drive therapeutic resistance, and foster disease recurrence following surgical resection. Emerging evidence indicates that this fibrinogen subunit actively reinforces stem-like characteristics within colorectal cancer cell populations. Three-dimensional spheroid formation assays demonstrate that overexpression markedly enhances sphere-forming capacity and self-renewal efficiency. Mechanistically, immunoprecipitation coupled with mass spectrometry reveals vital protein-protein interaction networks linking this molecule to the catenin complex. Specifically, the protein associates directly with beta-catenin and p120-catenin, stabilizing these molecules against premature proteasomal degradation. Additionally, interaction data reveal binding with prominent ubiquitin-specific proteases, particularly USP7 and USP10. These deubiquitinating enzymes protect critical transcription factors from ubiquitin-mediated breakdown, thereby sustaining canonical Wnt signaling pathways. Consequently, stabilized beta-catenin translocates into the nucleus to activate master pluripotency genes, expanding the cancer stem cell pool. Therefore, targeting the biochemical bridge between deubiquitinases and catenins represents an attractive therapeutic vulnerability. Disrupting these multimolecular assemblies could potentially eliminate refractory stem cell niches that survive standard fluoropyrimidine-based chemotherapies.

Clinical Prognostication and Postoperative Serum Monitoring

Accurate disease monitoring remains essential for detecting colorectal cancer recurrences before they manifest as unresectable metastatic lesions. Standard circulating biomarkers like carcinoembryonic antigen demonstrate variable sensitivity, underscoring the urgent need for supplemental blood-based indicators. Preliminary clinical analyses evaluating paired pre- and postoperative serum samples show dramatic elevations of circulating antigen in untreated patients. Importantly, serum concentrations exhibit a rapid and significant decline following complete curative oncologic resection. Consequently, persistent postoperative elevation or sudden secondary surges may serve as reliable early harbingers of residual disease or occult micrometastasis. Clinicians could potentially incorporate this serological test alongside routine diagnostic cross-sectional imaging to improve surveillance precision. Furthermore, integrating tissue expression scores with postoperative circulating values refines risk stratification algorithms for early-stage colorectal cancer patients. Patients presenting with high baseline concentrations and sluggish clearance patterns could undergo intensified adjuvant therapy protocols. Thus, monitoring dynamic changes in peripheral circulation offers an accessible, non-invasive method to evaluate surgical adequacy and track longitudinal tumor response.

Therapeutic Implications for Precision Colorectal Oncology

The identification of this multifaceted oncogenic pathway introduces novel therapeutic avenues for combating aggressive colorectal malignancies. Current chemotherapy regimens frequently fail to eliminate plastic cancer stem cell subpopulations, leading to eventual disease relapse. However, elucidating the physical association between this structural chain and ubiquitin-specific proteases exposes tractable pharmacological targets. Small-molecule inhibitors designed against USP7 or USP10 could theoretically destabilize the catenin complex, blunting stemness maintenance. Moreover, disrupting the aberrant crosstalk between neoplastic cells and the peritumoral fibrin network might restore cytotoxic drug sensitivity. Preclinical studies suggest that suppressing these downstream survival cascades sensitizes colon cancer cells to conventional oxaliplatin and irinotecan regimens. In addition, reversing epithelial-mesenchymal transition phenotypes may attenuate immunosuppressive microenvironments, enhancing the efficacy of modern checkpoint blockade immunotherapies. Translating these biological insights into routine practice requires robust validation through prospective multicentric clinical trials across diverse patient cohorts. Ultimately, targeting this signaling nexus holds great promise for overcoming chemoresistance and significantly improving long-term outcomes for patients facing advanced disease.

How does FGA expression influence colorectal cancer prognosis?

Elevated tissue and serum expression of this biomarker strongly correlates with aggressive tumor behavior, advanced clinical staging, and extensive lymphatic permeation. Patients exhibiting high levels demonstrate significantly shorter overall survival and higher recurrence rates compared to those with low expression. Consequently, oncologists can utilize these expression profiles as independent prognostic indicators, allowing teams to identify high-risk individuals requiring intensified systemic therapy and closer postoperative surveillance.

What molecular mechanisms link FGA to cancer stem cell properties?

The molecule interacts directly with key deubiquitinating enzymes, specifically USP7 and USP10, alongside beta-catenin and p120-catenin complexes. This physical association protects catenin proteins from normal proteasomal degradation, thereby amplifying intracellular Wnt signaling pathways. As a result, malignant cells upregulate transcription factors essential for stemness, self-renewal, and 3D spheroid formation. Furthermore, this sustained signaling cascade drives phenotypic plasticity, enabling colon cancer cells to resist standard cytotoxic chemotherapy.

Can postoperative serum FGA serve as a non-invasive surveillance biomarker?

Clinical evidence demonstrates that elevated preoperative circulating levels decline sharply following successful radical surgical resection. Conversely, persistently high postoperative levels or subsequent serum elevations often indicate incomplete resection, occult micrometastases, or impending disease recurrence. Therefore, monitoring dynamic serum changes provides clinicians with a sensitive, minimally invasive surveillance tool. When combined with routine carcinoembryonic antigen testing and cross-sectional imaging, it substantially improves early detection of recurrent disease.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Lin H et al. Fibrinogen Alpha Chain (FGA) Associates With Epithelial-Mesenchymal Transition, Stemness, and the USP-Catenin Complex in Colorectal Cancer. Stem Cells Int. 2026 undefined undefined. doi: 10.1155/sci/9599574. PMID: 42898796.
2. Jiang W, Wang D, Yu J. Recent Advances in Fibrinogen Research in Colorectal Cancer. Journal of Biosciences and Medicines. 2023;11(4):28-38.
3. Zhang X, Chen Y, Wang Z. Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in colorectal cancer: a meta-analysis. Frontiers in Oncology. 2025;15:1542101.